SGNDV-001: disitamab vedotin with pembrolizumab in HER2-expressing locally advanced or metastatic urothelial carcinoma. Powles TB, Grande E, Alimohamed N, Oliveira N, et al. Future Oncol 2025;21:2705-2712.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Powles TB, Grande E, Alimohamed N, Oliveira N, et al. SGNDV-001: disitamab vedotin with pembrolizumab in HER2-expressing locally advanced or metastatic urothelial carcinoma. Future Oncol 2025;21:2705-2712.
PMID: 40728126